Octapharma Expects To Have Octagam Back On the Market By Year's End
This article was originally published in The Pink Sheet Daily
Executive Summary
The company withdraws its IVIG Octagam 5% from the U.S. market following increased reports of thromboembolic events; it is challenging EMA's recommendation to withdraw the 10% formulation in Europe.